Infectious Disease
42 videos · last 6 months shuffled daily, then older videos newest first
▶
25:09 Clinical Trial Landscape in ME/CFS and Long COVID
Danielle Meadows, PhD, of the Open Medicine Foundation reviews the clinical trial landscape in ME/CFS and Long COVID, in a talk posted by Stanford's ME/CFS Collaborative Research Center.
▶
5:10 A Steroid-Sparing Approach to Leprosy Reactions in Nepal
Researchers led by Mahesh Shah from Anandaban Hospital in Nepal outline a protocol for an open-label Phase 2 pilot study evaluating dovramilast for patients experiencing Erythema Nodosum Leprosum (ENL).
▶
51:58 REMAP-CAP Results Oseltamivir in Critically Ill Influenza Patients
Dr. Srinivas Murthy, Dr. Thomas Hills and Dr. Lindsay Berry discuss on Berry Consultants' In the Interim podcast the REMAP-CAP results finding oseltamivir did not reduce 90-day mortality in critically ill influenza patients.
▶
5:53 S9, Ep 15- COVID-19 Isn't Over for Everyone: Why FDA's Next Decision Matters for Patients
Steven Newmark breaks down the U.S. Department of Health and Human Services decision to phase out COVID-19 Emergency Use Authorizations, and why it matters for people who are immunocompromised.
▶
39:11 Planning Around a Respiratory Season That Won’t Hold Still
David LaMarche of ERA Health Research, a site network in Washington state and West Texas, explains why respiratory trials planned on last year's calendar miss the season and how sponsors can activate sites earlier, on a DCN Dx podcast.
▶
1:04:22 Long COVID Trials and Genetic Analysis: An Update
Angela M. Cheung, MD, PhD, RECLAIM lead PI at the University of Toronto, and Hanna M Ollila, PhD, of FIMM and Massachusetts General Hospital review completed and ongoing Long COVID intervention trials and genetic analysis for Long COVID Web.
▶
47:48 OPTIMA-AF: One Month of Dual Therapy After PCI in AF
Yohei Sotomi, MD, PhD, of The University of Osaka and Ken Kozuma, MD, PhD, of Teikyo University discuss the OPTIMA-AF trial of shortened antithrombotic therapy after PCI in atrial fibrillation, from enrollment challenges to publication in The Lancet.
▶
4:52 A Young Hematologic Oncologist's Research Career
Luis Malpica Castillo, MD, of the Department of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center, describes how his clinical research interests began in infectious disease and HTLV-1 and led him to lymphoma, for Blood Cancers Today.
▶
25:28 Personalised Melanoma Vaccine and US mRNA Research Funding
BBC News speaks to Tom Whipple, host of BBC Inside Science, about a personalised mRNA vaccine that stopped melanoma returning in a trial, and how US cuts to mRNA vaccine research funding could affect health outcomes.
▶
2:10 Canada Approves Trial for mRNA Ebola Vaccine
CBC News on Health Canada approving a Phase 1 trial of Moderna's mRNA vaccine for the Bundibugyo strain of Ebola.
▶
59:06 Community Update: Infection Research
Rebekah Dedrick, PhD, Stacy Martiniano, MD, and David Nichols, MD on phage therapy and difficult-to-treat bacteria in cystic fibrosis, moderated by Sammi Marino, who has CF and has been treated for a mycobacterial lung infection.
▶
12:17 Complex PK/PD Modelling in Phoenix and RsNLME
Certara scientists show how its Phoenix and RsNLME software handle complex population PK/PD modelling, through case studies on malaria parasite dynamics and G-CSF pharmacology.
▶
1:00:10 How RECOVER-TLC Clinical Trials Work
The Foundation for the National Institutes of Health presents an overview of how RECOVER-TLC clinical trials work, the steps taken to protect participant safety, and how findings can affect clinical practice, for people considering taking part.
▶
27:03 Adaptive Bayesian Platform Trials in Clinical Care
Professor Nichol of University College Dublin, Director of the Irish Critical Care Clinical Trials Network, discusses adaptive Bayesian platform trials and global collaboration during the pandemic, for HRB TMRN.
▶
1:58 Evaluating Informed Consent Disclosures in AI Clinical Trials
Hankun Su of Xiangya Hospital, Central South University presents an analysis of 114 AI clinical trials on ClinicalTrials.gov that found 58% of consent documents did not disclose the AI type or intended use.
▶
1:25:51 Staphylococcus Aureus Bacteremia Trials: DOTS and SNAP
Thomas Holland (Duke University), Achim Kaasch (Otto von Guericke University Magdeburg) and Steven Tong (Peter Doherty Institute) present the DOTS trial of dalbavancin, early oral switch and the SNAP trial in S. aureus bacteremia, for ISAC.
▶
4:57 DOTS and PeterPen Trials in Bloodstream Infections
Megan Klatt, PharmD, discusses DOTS data on dalbavancin for complicated Staphylococcus aureus bacteremia and PeterPen interim results for ESBL bloodstream infections, and how they may affect practice and stewardship, for Contagion Live.
▶
1:37 25 at 25: PROUD - Preventing HIV Infections
The UCL Innovative Clinical Trials Unit looks back at the PROUD study, whose 2015 results showed a daily pill could substantially reduce new HIV infections among men who have sex with men.
▶
50:54 REGENCY: Obinutuzumab in Lupus Nephritis
Brad Rovin, MD, of Ohio State University Wexner Medical Center and Ana Malvar, MD, of Hospital Fernandez in Buenos Aires present the background and central results of the phase 3 REGENCY study of obinutuzumab in active lupus nephritis, for MARKUS at HOMe.
▶
6:24 "Data Integrity" at Texas Site During Pfizer COVID Vaccine Clinical Trial
BMJ interviews a whistleblower who discusses "data integrity" and other issues with a vendor in Texas during a trial of a Pfizer COVID-19 vaccine.
▶
4:20 HIV Vaccines at Night, Are Big and Bright, Deep in the Heart of Texas
A Texas physician, Dr. Barbara Taylor of University Health, discusses clinical trials of a HIV vaccine with a local news station.
▶
18:55 AGILE: An Adaptive Clinical Trial Using Patient Recruitment, Math and Statistics to Test New COVID Drugs
Andrew Titman from Lancaster University discusses the The AGILE Clinical Trial; a Phase 1/Phase 2a adaptive clinical trial testing new drugs aimed at treating COVID-19 including (as of the time of the video) Molnupiravir (Legervrio) and Sotrovimab (marketed as Xevudy, from GlaxoSmithKline and Vir Biotechnology).
▶
2:14 Mpox EMA Regulatory Pathway
GeoVax has received favourable scientific advice from the European Medicines Agency on GEO-MVA, supporting a streamlined route toward conditional approval of its mpox vaccine.
▶
1:27:07 Preparing U.S. Clinical Trials Infrastructure for Emergencies: A White House Virtual Roundtable
A video from the US Office of the National Coordinator for Health IT looks at ways of addressing conducting clinical trials during the next pandemic using lessons from the COVID-19 pandemic.